MINIREVIEW
Clinical evaluation
Obviously, not all documented bradycardia needs treatment and, conversely, undocumented but sus pected bradycardia may need backup measures to avoid asystole. Overall, therapy for bradycardia aims to (1) avoid asystole, (2) improve haemodynamic status, or (table 1) . AVB III may oc cur at both nodal as well as infranodal levels, although the latter is more frequent. Highgrade AVB is defined as ≥3:1 AVB. A common mistake is to misdiagnose AVB III by failing to recognise conducted P waves ( fig. 1 ).
In 2015, the European Resuscitation Council published guidelines on advanced life support [1] , which include an algorithm for the acute management of bradycardia Patients admitted with bradycardia may present with a variety of clinical pictures, ranging from fatigue to syncope and cardiac arrest. It is important to be able to identify the mechanism of bradycardia in order to distinguish benign from lifeth reatening situations. 6 ). In the event of undersensing, unnecessary pacing may be delivered (which may be potentially proarrhyth mic if it falls on a T wave).
In the case of oversensing (e.g., of artefacts), pacing may not be delivered (even in the case of asystole). As sensitivity levels usually cannot be modified, a differ ent lead vector needs to be chosen if there are sensing issues. As the external defibrillator may rely on cable electrodes for sensing, these should be properly fas tened (if necessary secured by tape).
The backup pacing rate is usually set to a low value (e.g., 30 bpm) to avoid unnecessary pacing, and should be set with an output that is likely to result in capture e.g., 160 mA).
If transcutaneous pacing is expected to be ineffective (e.g., in an obese patient), it is wise to test capture first (see fig. 5 ). If necessary, patients may be sedated with analgesia.
Transoesophaeal pacing
This modality has been abandoned at our institution.
A pacing wire is inserted into the oesophagus via the nose in order to pace the left atrium (which lies just an teriorly).
This modality is therefore not suitable for pacing in cases of AV block, and also provides inconsistent cap ture. 
Transvenous pacing
Temporary transvenous pacing doubles the risk of sub sequent permanent pacemaker infection [3] , and is as sociated with a risk of serious complications such as perforation and tamponade.
According to the 2013 European Society of Cardiology (ESC) guidelines on pacing [4] , temporary transvenous pacing should be used "only as a last resort when chronotropic drugs (e.g., isoproterenol, epinephrine, etc) are insufficient" and "should be limited to cases of (i) highdegree AV block without escape rhythm, (ii) lifethreatening bradyarrhythmias, such as those that occur during interventional procedures (e.g., during percutaneous coronary intervention, etc) or, rarely, in acute settings such as acute myocardial infarction, drug toxicity or concomitant systemic infection." 7 ).
When temporary pacing is required for more than a few days or in the atrium, a standard pacemaker screw in lead may be implanted via the internal jugular vein and connected to a recycled pacemaker ( fig. 8 ). This al lows pacing for up to 6 weeks [6] or more, allows mobi lisation (and in selected cases even temporary dis charge) of the patient, provides reliable pacing and sensing, and has a lesser risk of perforation than with temporary wires (which are stiffer). gency medical teams should be well trained in the de livery of these therapies, as they may be life saving.
Conclusions
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